Company news
Moleculin Biotech, Inc. (NASDAQ:MBRX) news
Moleculin Biotech, Inc. news releases on 6ix. Latest, Aug 14, 2025: Moleculin to Present at the Webull Financial Corporate Connect Webinar Series…
Press releases — page 2
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 14, 2025
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
August 13, 2025
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
August 6, 2025
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
July 30, 2025
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
July 22, 2025
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
July 17, 2025
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
July 9, 2025
Moleculin Announces $5.9 Million Public Offering
June 20, 2025
Moleculin Participates in Virtual Investor “What This Means” Segment
June 18, 2025
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
June 18, 2025
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
June 5, 2025
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
June 4, 2025
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
May 12, 2025
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
May 7, 2025
Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
May 6, 2025
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
May 5, 2025
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
April 29, 2025
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 17, 2025
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
April 1, 2025
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
March 24, 2025
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
March 19, 2025
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
March 11, 2025
Moleculin to Present at the 37th Annual ROTH Conference
March 10, 2025
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
March 6, 2025
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
March 3, 2025
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
February 25, 2025
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
February 12, 2025
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
February 12, 2025
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
February 10, 2025
Moleculin Participates in Virtual Investor "What This Means" Segment
January 26, 2025
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
January 7, 2025
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
December 10, 2024
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
November 17, 2024
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
November 13, 2024
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
November 11, 2024
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 10, 2024
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
November 4, 2024
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
November 3, 2024
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
October 16, 2024
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
October 6, 2024
Moleculin to Present at Two Upcoming Investor Conferences
October 3, 2024
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
September 22, 2024
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
September 8, 2024
Moleculin Announces Closing of up to $16.5 Million Public Offering
August 18, 2024
Moleculin Announces Pricing of up to $16.5 Million Public Offering
August 15, 2024
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 13, 2024
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
July 31, 2024
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
July 9, 2024
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
June 13, 2024